Maximilian P Schmid1,2, Thomas Held1,3, Kristin Lang1,3, Klaus Herfarth1,3, Juliane Hörner-Rieber1,3,4, Semi B Harrabi1,3, Julius Moratin5, Christian Freudlsperger5, Karim Zaoui6, Jürgen Debus1,3,4, Sebastian Adeberg1,3. 1. Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany. 2. Department of Radiation Oncology-Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. 3. Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany. 4. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 5. Department of Oral and Maxillofacial Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany. 6. Department of Otorhinolaryngology, University of Heidelberg, 69120 Heidelberg, Germany.
Abstract
Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18-24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50-54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients.
Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18-24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50-54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients.
Entities:
Keywords:
C12; head and neck cancer; particle therapy
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Karen Lossner; Thomas Haberer; Oliver Jäkel; Marc W Münter; Jürgen Debus Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-19 Impact factor: 7.038
Authors: William M Mendenhall; Christopher G Morris; Robert J Amdur; John W Werning; Douglas B Villaret Journal: Cancer Date: 2005-06-15 Impact factor: 6.860
Authors: David M Neskey; Jonah D Klein; Stephanie Hicks; Adam S Garden; Diana M Bell; Adel K El-Naggar; Merrill S Kies; Randal S Weber; Michael E Kupferman Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-11 Impact factor: 6.223
Authors: Joseph Zenga; Anuurag S Parikh; Kevin S Emerick; Derrick T Lin; William C Faquin; Daniel G Deschler Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223
Authors: Claudia Scherl; Masanari G Kato; Evren Erkul; Evan M Graboyes; Shaun A Nguyen; Angela C Chi; Patrick F Morgan; Terry A Day Journal: Oral Oncol Date: 2018-05-15 Impact factor: 5.337
Authors: A D Jensen; M Poulakis; V Vanoni; M Uhl; N Chaudhri; P A Federspil; K Freier; J Krauss; J Debus Journal: Radiat Oncol Date: 2016-07-07 Impact factor: 3.481